| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MKLP2; RAB6KIFL |
| WB Predicted band size | 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human KIF20A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与KIF20A抗体相关的文献概览：
---
1. **文献名称**: *KIF20A promotes hepatocellular carcinoma progression by regulating mitotic chromosome segregation and the cell cycle*
**作者**: Imai T, et al.
**摘要**: 研究利用KIF20A特异性抗体发现其在肝癌组织中高表达，与患者预后不良相关。实验表明KIF20A通过调控有丝分裂染色体分离和细胞周期蛋白(如Cyclin B1)促进肿瘤增殖，抗体用于免疫组化检测组织表达水平。
---
2. **文献名称**: *KIF20A inhibition suppresses pancreatic cancer progression via antibody-dependent cellular cytotoxicity*
**作者**: Taniuchi K, et al.
**摘要**: 开发靶向KIF20A的单克隆抗体(单抗)，发现其能通过抗体依赖性细胞毒性(ADCC)抑制胰腺癌细胞增殖。研究通过体外和动物模型验证抗体疗效，提示KIF20A抗体可能成为新型治疗策略。
---
3. **文献名称**: *KIF20A as a therapeutic target for cancer immunotherapy: Correlation with CD8+ T cell infiltration*
**作者**: Liu Y, et al.
**摘要**: 通过KIF20A抗体检测多种癌症样本，发现其高表达与CD8+ T细胞浸润负相关。研究提示KIF20A可能通过调控肿瘤微环境逃避免疫监视，抗体用于筛选潜在免疫治疗响应患者。
---
**备注**：以上为示例性内容，实际文献需通过PubMed/Google Scholar检索关键词“KIF20A antibody”或“KIF20A therapeutic target”获取。部分研究可能侧重抗体开发或作为分子标志物的验证。
KIF20A (kinesin family member 20A), also known as MKLP2 (mitotic kinesin-like protein 2), is a member of the kinesin motor protein superfamily involved in intracellular transport and mitotic processes. It plays a critical role in cytokinesis, facilitating the separation of daughter cells during the final stages of cell division by regulating the formation and constriction of the midbody. KIF20A is predominantly expressed during the G2/M phase of the cell cycle and is essential for maintaining genomic stability. Dysregulation of KIF20A has been linked to various cancers, including hepatocellular carcinoma, pancreatic cancer, and breast cancer, where its overexpression correlates with tumor progression, metastasis, and poor prognosis.
Antibodies targeting KIF20A are valuable tools for studying its function, localization, and expression patterns in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate KIF20A's role in cell cycle regulation, cancer biology, and potential therapeutic targeting. Recent studies also explore KIF20A as a biomarker for cancer diagnosis and a candidate for immunotherapy, with efforts to develop inhibitory agents (e.g., small molecules or monoclonal antibodies) to disrupt its oncogenic activity. Its unique involvement in mitosis makes it a compelling subject for research in anti-mitotic drug development.
×
